Dive into the complex world of Phase I clinical trials, where healthy volunteers test new drugs for safety in exchange for financial compensation. Discover the unspoken dynamics and perverse incentives that lead participants to strategically manage disclosures and navigate strict exclusion criteria to maintain eligibility and maximize their income. Understand the prevalent "better safe than sorry" atmosphere that shapes this challenging research environment and influences participant behavior.

The human brain, an astonishing network of 85 billion nerve cells, stands as the control tower of our existence, orchestrating every thought, emotion, and movement. It remains a "final frontier" for scientific exploration, much like the deepest oceans or distant galaxies, holding secrets that promise to revolutionize medicine

Explore the latest setbacks for Pfizer's sickle cell disease portfolio as its investigational P-selectin inhibitor, inclacumab, fails to meet its primary endpoint

Lantern Pharma has successfully completed targeted patient enrollment in Japan ahead of schedule for its multi-centre Phase II HARMONIC clinical trial of LP-300. This trial evaluates the safety and efficacy of LP-300, a disulfide small molecule, alongside standard-of-care chemotherapy for never-smoker NSCLC patients who have relapsed after TKI treatment

Clinical trials, the essential process by which new medical treatments are tested and brought to patients, are currently facing a profound crisis. Industry leaders are sounding the alarm, stating that the existing models are simply not sustainable and that without urgent, transformative change,

In the dynamic world of medical research, breakthroughs often emerge from a deep understanding of the body's intricate systems and a dedication to addressing persistent health challenges. One such exciting development comes from Windward Bio

Delve into the complexities of Myasthenia Gravis (MG), a heterogeneous neuromuscular disorder, and explore the evolution of standardized clinical scales and questionnaires used as outcome measures in clinical trials. Understand the shift from objective assessments to patient-reported outcomes (PROs), including key scales like QMG, MG-ADL, MGC, and QOL15(r)

The future of Alzheimer's disease research is brighter than ever! Discover how groundbreaking strategies, including innovative blood-based biomarker tests, virtual clinical trials, and culturally-informed community engagement, are dramatically increasing diverse participation and accelerating the development of urgently needed AD therapies

Alzheimer's disease (AD) is a devastating condition that relentlessly strips away memories, independence, and the very essence of an individual. It impacts millions globally, and the urgent need for effective new therapies cannot be overstated.

Discover how Walgreens is redefining clinical research, transforming patient engagement and recruitment for sponsors. Leveraging advanced AI models and predictive modeling technologies, we identify and match eligible patients to trials, often exceeding recruitment timelines

EyePoint Pharmaceuticals has successfully concluded Phase III enrollment for Duravyu (EYP-1901), a groundbreaking sustained-release therapy for wet Age-related Macular Degeneration (wet AMD). With over 400 subjects across the pivotal LUCIA and LUGANO trials

Breaking News: Get the full, transparent details on why Viatris's investigational MR-139 (pimecrolimus 0.3%) ophthalmic ointment for blepharitis failed its Phase III trial. Discover how the therapy did not meet its primary endpoint of complete resolution of debris after six weeks of twice-daily dosing.

Discover encouraging results from BioAtla's Phase I trial of BA3182 for heavily pretreated metastatic adenocarcinoma. This innovative dual-conditionally active biologic (CAB) therapy, designed to minimize off-target toxicities, has demonstrated a reassuring safety profile with predominantly low-grade and manageable adverse events. The study has observed objective tumour size decreases in five subjects across various cancer types, including two colorectal carcinoma subjects with impressive progression-free intervals of 11 and 14 months. With ongoing dose escalation, updated Phase I data are anticipated later this year, highlighting the potential of BA3182 as a new treatment option.

This study investigates the complex relationship between holding dialectical views on contradictions and psychological well-being, specifically examining depressive symptoms and life satisfaction. It explores the moderating roles of culture (European American vs. Asian American) and age, and the mediating role of mindfulness facets. Findings indicate that dialectical views are associated with increased depressive symptoms and lower life satisfaction primarily among younger European Americans,